PIQUR Therapeutics AG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PIQUR Therapeutics AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11158
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PIQUR Therapeutics AG (PIQUR) is a developer of anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipeline products comprise PQR-309, PQR-620, PQR-530, PQR-514, PQR-6XX, and PI3K/mTOR inhibitors. PIQUR’s lead compound PQR309, is a potent small molecule with balanced pan-PI3KmTOR selectivity. PIQUR’s target therapy areas include oncology, central nervous system, ophthalmology, and dermatology, among others. The company conducts research in the areas of oncology. It serves patients and the medical communities across Switzerland. PIQUR is headquartered in Basel, Switzerland.

PIQUR Therapeutics AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10
PIQUR Therapeutics Raises Additional US$16 Million In Series A Financing 11
PIQUR Therapeutics Raises US$20 Million In Series A Financing 12
PIQUR Therapeutics Raises Funds in Extended Seed Financing 13
PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14
Partnerships 15
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15
Eisai Enters into Agreement with PIQUR Therapeutics 16
Licensing Agreements 17
PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17
PIQUR Therapeutics AG – Key Competitors 18
PIQUR Therapeutics AG – Key Employees 19
PIQUR Therapeutics AG – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product Approvals 21
Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Key Facts 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PIQUR Therapeutics AG, Deals By Therapy Area, 2012 to YTD 2018 8
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10
PIQUR Therapeutics Raises Additional US$16 Million In Series A Financing 11
PIQUR Therapeutics Raises US$20 Million In Series A Financing 12
PIQUR Therapeutics Raises Funds in Extended Seed Financing 13
PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15
Eisai Enters into Agreement with PIQUR Therapeutics 16
PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17
PIQUR Therapeutics AG, Key Competitors 18
PIQUR Therapeutics AG, Key Employees 19

List of Figures
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PIQUR Therapeutics AG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Addison Lee Group:企業の戦略的SWOT分析
    Addison Lee Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • TauRx Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TauRx Pharmaceuticals Ltd (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. Its pipeline products include LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal demen …
  • AnGes Inc (4563):医療機器:M&Aディール及び事業提携情報
    Summary AnGes Inc (AnGes) is a biopharmaceutical company which discovers and develops gene and nucleotide based drugs and reagents for use in functional analysis of genetic medication. The company specializes in research and development (R&D) and practical application of genetic medicine. It has two …
  • Tenaga Nasional Berhad:発電所・企業SWOT分析
    Tenaga Nasional Berhad – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employ …
  • Chrono Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products. The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes. Its wearable …
  • Liberty Star Uranium & Metals Corp (LBSR):企業の財務・戦略的SWOT分析
    Summary Liberty Star Uranium & Metals Corp (Liberty Star), formerly Liberty Star Gold Corp is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration, operations, management, mining, production, and development of gold, copp …
  • Korab Resources Ltd (KOR):企業の財務・戦略的SWOT分析
    Summary Korab Resources Ltd (Korab) is a mining exploration company. The company’s business activities include evaluation, exploration, acquisition, production, and development of mineral resource properties. It explores for gold, potash, silver, tin, copper, rare earths, nickel, lead, zinc, magnesi …
  • Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Noble Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Noble Energy Inc (Noble) is an independent energy company that explores for and produces crude oil, natural gas and natural gas liquids (NGLs). The company’s portfolio includes both US unconventiona …
  • Hosken Consolidated Investments Ltd (HCI):企業の財務・戦略的SWOT分析
    Hosken Consolidated Investments Ltd (HCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Coherus BioSciences Inc (CHRS):企業の財務・戦略的SWOT分析
    Summary Coherus BioSciences Inc (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used …
  • Yahoo Japan Corporation (4689):企業の財務・戦略的SWOT分析
    Yahoo Japan Corporation (4689) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Fortum Corporation:企業の戦略・SWOT・財務情報
    Fortum Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Carr’s Group Plc (CARR):企業の財務・戦略的SWOT分析
    Carr's Group Plc (CARR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Zeta Petroleum Plc (ZTA):企業の財務・戦略的SWOT分析
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Zeta’s …
  • ALLETE Inc (ALE)-エネルギー分野:企業M&A・提携分析
    Summary ALLETE, Inc. (ALLETE) is an energy company that operates varied businesses in the energy sector. It has interests in mining facilities; electricity generation, transmission, and distribution assets; and water management businesses. It provides energy in the upper Midwest in the US; and inves …
  • Bonnier AB:企業の戦略的SWOT分析
    Bonnier AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Burwill Holdings Limited:企業の戦略・SWOT・財務情報
    Burwill Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Burwill Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Fairfax Media Limited:企業の戦略・SWOT・財務情報
    Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report Summary Fairfax Media Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Nippon Telegraph and Telephone Corporation:企業の戦略・SWOT・財務分析
    Nippon Telegraph and Telephone Corporation - Strategy, SWOT and Corporate Finance Report Summary Nippon Telegraph and Telephone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Le Chateau Inc. (CTU):企業の財務・戦略的SWOT分析
    Le Chateau Inc. (CTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆